Both in vivo and in vitro experiments have demonstrated the significant therapeutic efficacy of BMPs in various ocular disorders, including myopia, corneal opacity, cataract, uveal melanoma, retinal detachment and other eye diseases. This evidence concerns the gene CLN5 and uveal melanoma.